National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Niraparib (Zejula®) which is indicated as monotherapy for maintenance treatment of adult patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

NCPE Assessment Process Complete
Rapid review commissioned 01/06/2018
Rapid review completed 21/06/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of niraparib compared with the current standard of care
Full pharmacoeconomic assessment commissioned by HSE 27/06/2018
Pre submission consultation with Applicant 14/08/2018
Submission received from Applicant 09/01/2019
Preliminary review sent to Applicant 21/03/2019
NCPE assessment re-commenced 23/04/2019
Factual accuracy sent to Applicant 19/07/2019
NCPE assessment re-commenced 26/07/2019
NCPE assessment completed 14/08/2019
NCPE assessment outcome The NCPE recommends that niraparib (Zejula®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments.*


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.